Skip to content
Capsule Allopathic

Omnia 2.5 mg capsule

Generic: Mavacamten

Company: Incepta Pharmaceuticals Ltd.. Prices are as listed on BestinMeds; your pharmacy price may differ.

Strength2.5 mg
PackStrip: 150.00 taka

Reviewed by: not listed yet. Source: not listed yet.

Last updated May 5, 2026.

Compare

Same generic, same strength

Sorted by price per capsule. Ask your pharmacist before you switch brands.

Mavacamten 2.5 mg capsules

Prices as listed on BestinMeds.

2 brands listed
Camzoy15.00 taka per capsule
Omnia (this medicine)15.00 taka per capsule

Advertisement

Google Ads 970 x 250
Google Ads 300 x 250
Medicine guide

About this medicine

What this medicine is for, how to take it, and what to watch for.

Read the full Mavacamten guide

Indications

Mavacamten is indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms.

Dosage and administration

The recommended starting dose is 5 mg orally once daily without regard to food; allowable subsequent doses with titration are 2.5 mg, 5 mg, 10 mg, or 15 mg orally once daily. The maximum recommended dose is 15 mg orally once daily. Patients may develop heart failure while taking Mavacamten. Regular LVEF and Valsalva left ventricular outflow tract (LVOT) gradient assessment is required for careful titration to achieve an appropriate target Valsalva LVOT gradient, while maintaining LVEF ≥50% and avoiding heart failure symptoms. Daily dosing takes weeks to reach steady-state drug levels and therapeutic effects, and genetic variation in metabolism and drug interactions can cause large differences in exposure. When initiating or titrating Mavacamten, first consider LVEF then consider the Valsalva LVOT gradient and patient clinical status to guide appropriate Mavacamten dosing. Follow the algorithms for Initiation and Maintenance for appropriate Mavacamten dosing and monitoring schedules. If LVEF

Side effects

This information is not available. Ask your doctor or pharmacist.

Precautions and warnings

Heart Failure: Consider interruption of CAMZYOS (mavacamten) in patients with intercurrent illness. Drug Interactions Leading to Heart Failure or Loss of Effectiveness: Advise patients of the potential for drug interactions including with over-the-counter medications. Embryo-Fetal Toxicity: May cause fetal harm. Advise females of reproductive potential to use effective contraception until 4 months after the last dose. Use a contraceptive not affected by CYP450 enzyme induction or add nonhormonal contraception.

Pregnancy and lactation

The presence of Mavacamten in human or animal milk, the drug’s effects on the breastfed infant, and the effects on milk production are unknown. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Mavacamten and any potential adverse effects on the breastfed child from Mavacamten or from the underlying maternal condition.

Clinical details

BestinMeds shares medicine information to help you compare. It does not replace advice from your doctor or pharmacist.

Advertisement

Google Ads 970 x 250
Google Ads 300 x 250

Advertisement

Google Ads 970 x 250
Google Ads 300 x 250